To investigate whether inhibiting AXL with R428 could provide a clinical advantage in the treatment of recalcitrant tumors with epirubicin, we used a tumor xenograft mouse model of epirubicin‐resistant FLO‐1 cancer cells that were assessed as shown in Fig. 1. The gene discussed is AXL; the disease is neoplasm.